IDXX Stock Analysis — Idexx Laboratories
Sector: Healthcare Diagnostics
AI Verdict
Idexx trades at 39.6x next year's earnings for just 9.8% expected EPS growth—you're paying a premium the numbers don't yet support, but the moat from recurring diagnostics and software integration makes the growth outlook more credible than most.
Competitive Moat
Idexx dominates the veterinary diagnostics market with proprietary analyzers and a vast installed base in animal hospitals, making switching costly for clinics. Their recurring revenue from consumables and integrated software platforms creates a sticky ecosystem that competitors struggle to dislodge.
Summary
Idexx's recurring diagnostic consumables and software lock-in are driving a 31.24% one-year return despite a premium valuation.
Where It Stands
Shares are up 31.24% in the past year, the RSI at 42.6 signals cooling momentum, and the stock trades at 39.6x forward earnings versus a healthcare sector median of 22x.
Key Metrics
- RSI: 42.6 — Neutral
- Trailing P/E: 43.5x
- Forward P/E: 39.6x
- PEG Ratio: 4.03
- Earnings Growth: +0.1%
- Revenue Growth: +0.1%
- Market Cap: $45.3B
- 1-Year Return: 31.24%
- 52-Week High: $769.98
- 52-Week Low: $427.70
Analyst Consensus
16 Buy · 6 Hold · 0 Sell (22 analysts)
Bull Case
The 9.8% forward EPS growth and 10.4% trailing revenue growth show steady expansion, supporting the premium for a business with sticky recurring revenues.
Bear Case
At 39.6x forward earnings and a PEG of 4.03, even a modest P/E compression to the sector median (22x) would cut the stock by over 40%.
Catalyst to Watch
Watch for new product launches or large competitor moves in veterinary diagnostics, as either could shake up Idexx's high-margin recurring revenue stream.